SECURITIES AND EXCHANGE COMMISSION
                         Washington, D. C.  20549

                                FORM 10-Q


               QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF
                   THE SECURITIES EXCHANGE ACT OF 1934


                    For the Quarter Ended October 1, 1995

                        Commission File Number 0-12948


                             CHEMFAB CORPORATION
               (Exact name of registrant as specified in its charter)


               Delaware                             03-0221503
               (State or other jurisdiction of    (I.R.S. Employer
               incorporation or organization)      Identification No.)

               701 Daniel Webster Highway 
               Merrimack, New Hampshire                     03054
               (Address of principal executive office)    (Zip Code)
                                 
               Registrant's telephone number including
               area code:  (603) 424-9000

                                 
               Indicate by check  mark whether the registrant (1) has filed
               all reports required to be filed  by Section 13 or 15 (d) of
               the Securities Exchange Act of 1934 during  the preceding 12
               months (or  for such shorter period that  the registrant was
               required  to file such reports), and (2) has been subject to
               such filing requirements for the past 90 days.

                               YES     X    NO_____.
                                    

               Indicate the  number of  shares outstanding  of each  of the
               issuer's  classes   of  common  stock,  as   of  the  latest
               practicable date.


               Class                         Outstanding at November 10, 1995
               Common Stock, $ .10 par value           5,271,221 shares


                                   CHEMFAB CORPORATION
                                          INDEX

                                          

               Part I - Financial Information:                    Page No.

                  Item 1 - Financial Statements

                       Consolidated Balance Sheets at October        3 - 4  
                       1, 1995 and June 30, 1995

                       Consolidated Statements of Income for             5  
                       the Three Months Ended October     
                       1, 1995 and October 2, 1994            

                       Consolidated Statements of Cash Flows             6
                       for the Three Months Ended October 1, 1995
                       and October 2, 1994

                       Notes to Consolidated Financial Statements    7 - 8  

                  Item 2 - Management's Discussion and Analysis     8 - 10
                           of Financial Condition and Results 
                           of Operations

               Part II - Other Information:                             10


                  Item 6(a) - Exhibits                                  10

               Signatures                                               11


<TABLE>
<S><C>

                        PART I - FINANCIAL INFORMATION
                        ------------------------------

                             CHEMFAB CORPORATION
                         CONSOLIDATED BALANCE SHEETS


                                                                  Oct. 1,           June 30,
                                                                   1995               1995
                                                               -------------      -------------
                                                                (Unaudited)
           Current assets:
               Cash and cash equivalents                     $    3,280,000     $    3,780,000
               Receivables:
                    Trade                                        14,875,000         16,009,000
                    Retainages                                      148,000            148,000
                    Other                                           220,000            324,000
               Costs and estimated earnings in excess of 
                   billings on uncompleted contracts              1,036,000            692,000
               Inventories                                       13,582,000         13,110,000
               Prepaid expenses, and other                        1,218,000            901,000
               Deferred tax assets                                1,203,000          1,152,000
                                                               ------------       ------------
               Total current assets                              35,562,000         36,116,000

               
               Property, plant and equipment at cost             37,387,000         36,869,000
                    Less accumulated depreciation
                       and amortization                          17,722,000         17,036,000
                                                               ------------       ------------
                                                                 19,665,000         19,833,000

               Goodwill, net                                     11,955,000         12,260,000
               Investments in joint ventures and 
                   other assets                                   2,414,000          2,410,000
                                                               ------------       ------------

               Total assets                                  $   69,596,000     $   70,619,000
                                                               ============       ============

</TABLE>

           See accompanying Notes to Consolidated Financial Statements


<TABLE>
<S><C>

                         CHEMFAB CORPORATION
                     CONSOLIDATED BALANCE SHEETS


                                                                  Oct. 1,           June 30,
                                                                   1995               1995     
                                                               -------------      -------------
                                                                (Unaudited)
           Current liabilities:
               Accounts payable and accrued
                    expenses                                 $    8,068,000     $    8,757,000
               Accrued income taxes                                 831,000          1,736,000
               Billings in excess of costs and 
                    estimated earnings on
                    uncompleted contracts                           135,000            122,000
                                                               -------------      -------------

               Total current liabilities                          9,034,000         10,615,000


           Long - term debt                                       7,085,000          8,132,000
           Deferred income taxes                                  1,526,000          1,551,000

           Shareholders' equity:
               Preferred stock, par value $.50:
                    authorized - 1,000,000 shares,
                    none issued                                      -                  -
               Common stock, par value $.10:
                    authorized - 15,000,000 shares;
                    issued and outstanding - 5,271,221
                    at October 1, 1995 and 5,235,646
                    at June 30, 1995                                527,000            524,000
               Additional paid-in capital                        16,968,000         16,609,000
               Retained earnings                                 34,910,000         33,551,000
               Foreign currency translation
                    adjustment                                     (454,000)          (363,000)
                                                               -------------      -------------

               Total shareholders' equity                        51,951,000         50,321,000
                                                               -------------      -------------

           Total liabilities and shareholders' equity        $   69,596,000     $   70,619,000
                                                               ============       ============

</TABLE>

           See accompanying Notes to Consolidated Financial Statements

<TABLE>
<S><C>

                            CHEMFAB CORPORATION
                     CONSOLIDATED STATEMENTS OF INCOME
                                (Unaudited)
                                
           
                                                            Three Months Ended
                                                       -----------------------------
                                                       Oct. 1, 1995     Oct. 2, 1994
                                                       ------------     ------------

        Net sales                                      $  18,466,000    $  13,722,000
        Cost of sales                                     12,567,000        9,359,000
                                                         -----------      -----------
        Gross Profit                                       5,899,000        4,363,000
        Selling, general and
           administrative expenses                         3,261,000        2,776,000
        Research and development expenses                    545,000          482,000
        Other (income), net                                   (1,000)          (6,000)
        Interest expense                                     183,000            7,000
        Interest income                                      (45,000)         (87,000)
        Results of equity operations                               0           23,000
                                                         -----------      -----------

        Income before income taxes                         1,956,000        1,168,000

        Provision for income taxes                           597,000          345,000
                                                         -----------      -----------

        Net income                                     $   1,359,000    $     823,000
                                                         ===========      ===========
        Weighted average common and
         common equivalent shares                          5,421,000        5,287,000
                                                         ===========      ===========

        Earnings per common share                              $0.25            $0.16
                                                               =====            =====

</TABLE>

        See accompanying Notes to Consolidated Financial Statements.

<TABLE>
<S><C>

                            CHEMFAB CORPORATION
                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                                (Unaudited)

                                                                         Three Months Ended
                                                                     -------------------------
                                                                     Oct.1, 1995    Oct.2, 1994
                                                                     -----------    -----------
    Cash flows from operating activities:

       Net income                                                  $  1,359,000   $    823,000

       Adjustments to reconcile net income to net
         cash provided by operations:
            Depreciation and amortization                             1,039,000        730,000

            Results of equity operations                                      0         23,000
            Change in assets and liabilities:
               Receivables                                            1,173,000        724,000
               Costs and estimated earnings in excess
                 of billings on uncompleted contracts, net             (344,000)        58,000
               Inventories                                             (504,000)    (2,158,000)
               Prepaid expenses and other                              (318,000)       (73,000)
               Other assets long-term                                   (98,000)       (71,000)
               Accounts payable and accrued expenses                   (562,000)      (358,000)
               Accrued income taxes                                    (901,000)       (57,000)
               Deferred tax liabilities                                 (25,000)             0
               Deferred tax assets                                      (51,000)             0
                                                                     -----------    -----------
               Total adjustments                                       (591,000)    (1,182,000)
                                                                     -----------    -----------
               Net cash provided by operations                          768,000       (359,000)

       Cash flows from investing activities:
            Capital expenditures (net)                                 (555,000)      (361,000)
                                                                     -----------    -----------

               Net cash used in investing activities                   (555,000)      (361,000)

       Cash flows from financing activities:
            Repayment of long-term debt                              (1,067,000)             0
            Proceeds from exercise of stock options                     365,000         89,000
                                                                     -----------    -----------

               Net cash (used in) provided by financing activities     (702,000)        89,000

       Effect of exchange rate changes on cash                          (11,000)       123,000
                                                                     -----------    -----------

       Net decrease in cash and cash equivalents                       (500,000)      (508,000)

       Cash and cash equivalents at beginning of year                 3,780,000      7,923,000
                                                                     -----------    -----------
                                                                          
       Cash and cash equivalents at end of period                  $  3,280,000   $  7,415,000
                                                                     ===========    ===========

      Interest paid                                                $    190,000   $      7,000
      Income taxes paid                                            $    936,000   $    511,000

</TABLE>

       See accompanying notes to the Consolidated Financial Statements



                        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

               Note 1 The  consolidated  financial  statements  of  Chemfab
                      Corporation (the  Company)  included in  this  report
                      reflect  all adjustments (consisting of only normally
                      recurring   accruals)  which,   in  the   opinion  of
                      management, are necessary for  a fair presentation of
                      the  consolidated  financial position  at  October 1,
                      1995  and   June  30,   1995  and   the  consolidated
                      statements  of income  and cash  flows for  the three
                      months  ended October  1, 1995  and October  2, 1994.
                      The unaudited results of  operations for the  interim
                      periods  reported are  not necessarily  indicative of
                      results to be expected for the year.


               Certain notes  and other information have  been condensed or
               omitted  from  these  interim  financial  statements.    The
               statements, therefore,  should be  read in conjunction  with
               the  consolidated financial  statements  and  related  notes
               included in  the Chemfab  Corporation Annual Report  on Form
               10-K for the year ended June 30, 1995 (file no. 0-12948).

               Note 2  Inventories consist of the following:
                                          
                                          
                                       October 1, 1995       June 30,1995
                                       ---------------       ------------
                      Finished Goods     $ 3,806,000          $3,953,000
                      Work in Process      5,230,000           5,089,000
                      Raw Materials        4,546,000           4,068,000
                                          __________          __________

                                         $13,582,000         $13,110,000


               Note 3  In  connection with obtaining incentive grants  from
               the   Industrial  Development   Authority  of   Ireland,  to
               subsidize investments in plant  and equipment in Ireland the
               Company's  Irish subsidiary, Chemfab  Europe, has  agreed to
               restrict   repatriation  of   410,000  Irish   pounds  (U.S.
               $663,000) of its  retained earnings to fund repayment of the
               grants in the event of default under the agreement.  Chemfab
               Corporation has also provided  a parent company guarantee in
               the event that the subsidiary's equity so restricted is  not
               sufficient to repay any amount due.


               Various  lawsuits  and  claims  are  pending  or  have  been
               asserted  against   the   Company,  including   the   matter
               previously disclosed by the Company involving the Bennington
               Landfill Superfund site,  in Bennington  Vermont.   Although
               the  outcome  of  such  matters  cannot  be  predicted  with
               certainty  and some  lawsuits or claims  may be  disposed of
               unfavorably  to  the   Company,  management  believes  their
               disposition, to  the extent  not covered by  insurance, will
               not  have  a  material   adverse  effect  on  the  Company's
               financial condition and results of operations.



               ITEM 2   Management's  Discussion and Analysis  of Financial
               Condition and Results of Operations

               Three Months Ended October 1, 1995

               Net Sales

               The Company's  consolidated net  sales for the  three months
               ended October  1, 1995,  the first  quarter of  fiscal 1996,
               increased 35%  to $18,466,000 from $13,722,000  for the same
               period in the prior year.  Measured on the basis of constant
               foreign currency exchange rates, current  year first quarter
               sales  would have  increased  34% over  sales  for the  same
               quarter a year ago.  Revenue growth was achieved in both the
               U.S.  and European  business  operations  and reflected  the
               positive impact  of the Company's  February 1995 acquisition
               of  the Tygaflor  fluoropolymer products  business based  in
               England.

               Engineered Products - U.S.  Sourced sales (which include all
               non-architectural  product  sales  from the  Company's  U.S.
               manufacturing  plants; principal geographic  markets are the
               Americas and the Far  East) decreased 3% to  $8,909,000 from
               $9,187,000  for the  same period  in the  prior year.   This
               sales decline resulted principally from relative softness in
               aerospace,   energy/environment   and  lab   test/healthcare
               markets during  the quarter.   It is expected  that revenues
               from U.S. Sourced - Engineered Products will strengthen over
               the remainder of the current fiscal year.

               Engineered Products -  Europe Sourced  sales (which  include
               product  sales from  the  Company's  European  manufacturing
               plants;  principal geographic  markets  are Western  Europe,
               Africa and  the Middle  East) increased 83%   to  $6,270,000
               from $3,418,000 for the same period in the  prior year.  Had
               foreign currency exchange rates  remained unchanged from the
               first  quarter of  fiscal 1995,  current year  first quarter
               sales  would have increased 81% over the same quarter in the
               prior year.  This increase was due primarily to the February
               1995  acquisition of  the  Tygaflor business.   Without  the
               benefit of  the acquisition,  it is estimated  that revenues
               would have increased approximately 6-8%. 

               Architectural  Product  sales increased  194%  to $3,287,000
               from $1,117,000  for the first  quarter of the  prior fiscal
               year.   Architectural products were principally  sold to the
               Company's Japanese joint venture company, Nitto Chemfab Co.,
               Ltd.,   during   the   first   quarter   of   fiscal   1996.
               Architectural product  sales are expected to  continue to be
               strong for the remainder  of the current year  due primarily
               to continued strong demand in the Japanese market.

               Gross Profit Margins

               Gross  profit margins as a percentage of net sales were 32%,
               unchanged from the first quarter of the prior year.



               Selling, Administrative, Research and Development Expenses

               Selling, general and  administrative expenses increased  17%
               to  $3,261,000  from $2,776,000  for  the  first quarter  of
               fiscal 1995.   Increased  expenditures were  principally the
               result  of the  combined effects of  the acquisition  of the
               Tygaflor business  and a  somewhat higher cost  structure to
               support the growth  of the underlying business.   Absent the
               impact  of  the  Tygaflor  business,  selling,  general  and
               administrative expenses would  have increased  approximately
               8% over  the level of the  first quarter of last  year.  The
               percentage of selling,  general and administrative  expenses
               to total revenues, decreased  to 18% as compared to  20% for
               the first quarter of fiscal 1995.


               Research and development expenses were $545,000, an increase
               of 13%  from last year's level  of $482,000.   This level of
               spending,  at  approximately  3%  of  total  revenues,    is
               consistent  with  recent,  as  well as  planned,  levels  of
               research and development spending.

               Interest Expense (Income)

               The  Company had net  interest expense  of $138,000  for the
               three month period  ended October 1,  1995, compared to  net
               interest  income of $80,000 for the same period in the prior
               year.    This  change was  principally  due  to  the use  of
               previously invested cash and the issuance of  long-term debt
               to  finance  the acquisition  of  the  Tygaflor business  in
               February, 1995.


               Liquidity and Capital Resources

               During  the three  month period  ended October 1,  1995, the
               Company  generated $768,000  of cash  from operations.   The
               Company invested  $555,000 in property, plant  and equipment
               additions and repaid $1,067,000 of its long-term debt.   The
               Company also received $365,000 in proceeds from the exercise
               of stock options during this period.

               Working  capital  increased  to $26,528,000  as  compared to
               $25,501,000 at the  end of fiscal  1995.  As  of October  1,
               1995,  the   Company  had  approximately  $6.6   million  of
               additional  credit   available   under  its   domestic   and
               international  borrowing  facilities.   Management  believes
               that  the combination of cash  on hand, cash  expected to be
               generated from operations, and available  credit facilities,
               will be  adequate to  finance operations during  fiscal 1996
               and to deal with  any liabilities or contingencies described
               in Note 3 to the Consolidated Financial Statements.


                 
                            PART II - OTHER INFORMATION


               ITEM 6 - Exhibits and Reports on Form 8-K

               6(a) Exhibits

                None

               6(b) Reports on Form 8-K

                None.  





                               CHEMFAB CORPORATION


                                   SIGNATURES

               PURSUANT TO THE REQUIREMENTS  OF THE SECURITIES EXCHANGE ACT
               OF  1934, THE REGISTRANT HAS  DULY CAUSED THIS  REPORT TO BE
               SIGNED  ON  ITS BEHALF  BY  THE  UNDERSIGNED THEREUNTO  DULY
               AUTHORIZED.


               CHEMFAB CORPORATION
               (Registrant)

                                   

               by:/S/ Duane C. Montopoli                     
               Duane C. Montopoli      
               President and Chief Executive Officer

                                   

               by:/S/ William H. Everett                     
               William H. Everett
               Vice President-Finance and Administration
               (Principal Financial Officer)


                                   
               by:/S/ Laurence E. Richard                   
               Laurence E. Richard
               Controller
               (Principal Accounting Officer)





               Date:  November 14, 1995